A common complication of chemotherapy is neurotoxicity that often manifests itself as peripheral neuropathy. Many cancer drugs can cause chemotherapy-induced peripheral neuropathy (CIPN), and the incidence can be up to 90%. A significant percentage of patients improve once the offending drug is stopped, but as much as 50% of the affected individuals are left with residual peripheral neuropathy that affects their quality of life. This review will focus on rodent models of CIPN, with special attention to outcome measures used to evaluate the effects of chemotherapy on the peripheral nervous system, and will critically review how faithful these models are to the human disease. READ MORE
Source:Â ILAR Journal/Oxford University Press